Speaking at CDMI Europe 2025, GlobalData pharma analyst George El-Helou says the use of AI in R&D could help mitigate patent ...

FL is the most common indolent form of B-cell NHL. Credit: Motortion Films/Shutterstock.com. At the American Society of Hematology (ASH) Annual Meeting, held on 6-9 December, results from the global, ...

Dyne Therapeutics reported six-month and 24-month data from the Phase I/II trial. Image credit: Sheldon Cooper / SOPA Images / LightRocket via Getty Images. Dyne Therapeutics is seeking US accelerated ...

ARCH Ventures-backed Paradigm Health has acquired Roche-owned Flatiron Health’s clinical research business, while closing an oversubscribed $78m Series B financing round to incorporate clinical trials ...

The safety profile of atogepant over the 24-week period aligned with earlier studies of its use in migraine prevention, with no new safety signals observed. Credit: Komsan Loonprom / Shutterstock.com.

BMS has now said that data from ADEPT-2 will be available in 2026. Image credit: HJBC / Shutterstock.com. Bristol Myers Squibb (BMS) has delayed the data readout from the Phase III ADEPT-2 trial of ...

Kelun-Biotech’s Sac-TMT has met its primary endpoint of PFS improvements in combination with MSD’s Keytruda in comparison to the checkpoint inhibitor alone in a Phase III trial. Image credit: Butusova ...

Takeda Pharmaceuticals’ dengue vaccine, Qdenga, has demonstrated long-term efficacy in preventing infections and hospitalisations in a seven-year Phase III study. Image credit: SILVIA MAQQ via ...

Produodopa is an alternative to AbbVie’s own Duodopa. Credit: Michael Vi via Shutterstock. On 9 January 2024, AbbVie announced the launch of Produodopa ...

The FDA has debuted a framework that is designed to help companies move away from the use of non-human primate preclinical toxicology testing. Image credit: Deniz_Guler via Shutterstock.com. The US ...

Novo Nordisk’s amylin agonist, amycretin, has met its key efficacy endpoints in a Phase II study in type 2 diabetes, meaning the Danish pharma will now take the drug to Phase III in the indication.